The role of glucagon in the artificial pancreas

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 6, 2016, Pages 476-479

  Haidar, Ahmad ^a   Smaoui, Mohamed Raef ^b,c   Legault, Laurent ^d   Rabasa Lhoret, Rémi ^b,c,e,f  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Montreal Diabetes Research Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PRAMLINTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ANIMAL; BLOOD; DRUG DELIVERY SYSTEM; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEMS; GLUCAGON; HUMANS; INSULIN; PANCREAS, ARTIFICIAL;

EID: 84968901955     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30006-7     Document Type: Note

References (15)

1. Heise T, Meneghini LF Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract 2014, 20:75-83.
2. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005, 54:1100-1107.
3. Haidar A, Elleri D, Kumareswaran K, et al. Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes. Diabetes Care 2013, 36:e173-e174.
4. El Youssef J, Castle JR, Bakhtiani PA, et al. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care 2014, 37:3054-3060.
5. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015, 373:2129-2140. for the APCam Consortium and AP@home Consortium.
6. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015, 3:17-26.
7. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010, 2:27ra.
8. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006, 55:3344-3350.
9. Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013, 36:838-844.
10. Massara F, Martelli S, Cagliero E, Camanni F, Molinatti GM Influence of glucagon on plasma levels of potassium in man. Diabetologia 1980, 19:414-417.
11. Parmley WW, Glick G, Sonnenblick EH Cardiovascular effects of glucagon in man. N Engl J Med 1968, 279:12-17.
12. Root MA Effect of chronic administration of glucagon to rats and rabbits. Proc Soc Exp Biol Med 1954, 87:108-110.
13. Cameron JM, Melrose AG Changes in liver, pancreatic and stomach morphology following chronic glucagon administration in guinea-pigs. Br J Exp Pathol 1962, 43:384-386.
14. Root MA Effect of glucagon on glycogen in rats and rabbits. Endocrinology 1956, 59:340-346.
15. Salter JM, Davidson IW, Best CH The pathologic effects of large amounts of glucagon. Diabetes 1957, 6:248-252.